loading
Precedente Chiudi:
$1.17
Aprire:
$1.16
Volume 24 ore:
86,084
Relative Volume:
0.01
Capitalizzazione di mercato:
$3.84M
Reddito:
-
Utile/perdita netta:
$-11.38M
Rapporto P/E:
-0.0436
EPS:
-27.73
Flusso di cassa netto:
$-12.72M
1 W Prestazione:
+6.14%
1M Prestazione:
-26.22%
6M Prestazione:
+40.09%
1 anno Prestazione:
-76.13%
Intervallo 1D:
Value
$1.15
$1.24
Intervallo di 1 settimana:
Value
$1.01
$1.24
Portata 52W:
Value
$0.0915
$14.75

Windtree Therapeutics Inc Stock (WINT) Company Profile

Name
Nome
Windtree Therapeutics Inc
Name
Telefono
(215) 488-9300
Name
Indirizzo
2600 KELLY ROAD, WARRINGTON, PA
Name
Dipendente
14
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
WINT's Discussions on Twitter

Confronta WINT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
WINT
Windtree Therapeutics Inc
1.21 3.84M 0 -11.38M -12.72M -27.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2020-06-26 Iniziato Ladenburg Thalmann Buy

Windtree Therapeutics Inc Borsa (WINT) Ultime notizie

pulisher
Apr 20, 2025

Windtree Therapeutics Reports 2024 Financial Results and Strategic Developments - MSN

Apr 20, 2025
pulisher
Apr 18, 2025

Windtree Therapeutics announces board member resignation By Investing.com - Investing.com Nigeria

Apr 18, 2025
pulisher
Apr 18, 2025

Windtree Therapeutics announces board member resignation - Investing.com Australia

Apr 18, 2025
pulisher
Apr 16, 2025

Windtree Therapeutics (WINT) Advances Clinical and Strategic Ini - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

Windtree Therapeutics Reports 2024 Progress and Strategy Shift - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

WINDTREE THERAPEUTICS INC /DE/ SEC 10-K Report - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Windtree Therapeutics reports FY24 EPS ($104.35) vs. ($4,718.84) last year - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Windtree Therapeutics sees cash runway through April - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Company Secures Additional Funding to Sustain Operations Through April 2025 | WINT Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Windtree Slashes Losses by $18.5M as Cardiogenic Shock Drug Shows Promise - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Growth in Short Interest - Defense World

Apr 15, 2025
pulisher
Apr 10, 2025

Windtree Therapeutics Issues Convertible Notes to Raise $250,000 - Investing.com Australia

Apr 10, 2025
pulisher
Apr 08, 2025

Windtree Therapeutics (WINT) to Release Earnings on Tuesday - Defense World

Apr 08, 2025
pulisher
Mar 31, 2025

Windtree Therapeutics Delays Annual Report Filing - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

WINT stock touches 52-week low at $1.32 amid steep annual decline - Investing.com

Mar 31, 2025
pulisher
Mar 29, 2025

Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Decline in Short Interest - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Windtree Therapeutics Regains Nasdaq Compliance - MSN

Mar 28, 2025
pulisher
Mar 27, 2025

Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MSN

Mar 27, 2025
pulisher
Mar 26, 2025

Windtree reports positive Phase 2b study on heart failure therapy - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cos - GuruFocus

Mar 26, 2025
pulisher
Mar 26, 2025

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Windtree Therapeutics Inc. (WINT) Soars 14.63% on Nasdaq Compliance - AInvest

Mar 26, 2025
pulisher
Mar 26, 2025

Massive 60% Cost Cut: How PHEXXI's New Deal Transforms Global Contraceptive Access - Stock Titan

Mar 26, 2025
pulisher
Mar 24, 2025

Windtree Therapeutics IncOn March 20, Entered License And Supply Agreement With Evofem BiosciencesSEC Filing - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Windtree Therapeutics regains compliance with Nasdaq listing rules - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Windtree Therapeutics Regains Compliance With Nasdaq Listing Rules For Continued Listing - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Windtree Therapeutics Regains Nasdaq Compliance Over Minimum Share Price Rule - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Windtree Therapeutics regains Nasdaq compliance - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Evofem Reports Fourth Consecutive Year of Net Sales Growth - Quantisnow

Mar 24, 2025
pulisher
Mar 24, 2025

Evofem Posts Record 4th Year Growth: Revenue Up 6% as Operating Costs Plunge 27% - Stock Titan

Mar 24, 2025
pulisher
Mar 24, 2025

Windtree Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules - The Manila Times

Mar 24, 2025
pulisher
Mar 24, 2025

Windtree Therapeutics Dodges Delisting: How The Biotech Company Saved Its Nasdaq Status - Stock Titan

Mar 24, 2025
pulisher
Mar 24, 2025

Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 24, 2025
pulisher
Mar 22, 2025

Biotech Stocks To Consider – March 20th - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 21, 2025
pulisher
Mar 21, 2025

Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI® - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI - MyChesCo

Mar 21, 2025
pulisher
Mar 20, 2025

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

Windtree shares rise as it announces agreement to become sourcing partner for Evofem - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

Windtree Therapeutics (WINT) Climb Amid New Licensing Deal - Stocks Telegraph

Mar 20, 2025
pulisher
Mar 20, 2025

Another Day, Another Biotech Ripping Before The Bell - The Globe and Mail

Mar 20, 2025
pulisher
Mar 20, 2025

Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

What's Going On With Windtree Therapeutics Shares Thursday? - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

Windtree to become sourcing partner for Evofem Biosciences - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Windtree Signs Deal to Become Sourcing Partner for Evofem's Contraceptive Vaginal Gel; Shares Rise - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Windtree partners with Evofem for contraceptive gel supply - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Windtree's Game-Changing Deal: Manufacturing Rights to $19M FDA-Approved Contraceptive - Stock Titan

Mar 20, 2025

Windtree Therapeutics Inc Azioni (WINT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Capitalizzazione:     |  Volume (24 ore):